Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients
Open Access
- 24 August 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8), e43393
- https://doi.org/10.1371/journal.pone.0043393
Abstract
In most cases of cervical cancers, HPV DNA is integrated into the genome of carcinoma cells. This mutational insertion constitutes a highly specific molecular marker of tumor DNA for every patient. Circulating tumor DNA (ctDNA) is an emerging marker of tumor dynamics which detection requires specific molecular motif. To determine whether the sequence of the cell-viral junction could be used in clinical practice as a specific marker of ctDNA, we analyzed a series of cervical cancer patient serums. Serum specimens of 16 patients diagnosed with HPV16/18-associated cervical cancer, and for which the viral integration locus had been previously localized, were analyzed. Sequential serum specimens, taken at different times during the course of the disease, were also available for two of these cases. ctDNA was found in 11 out of 13 patients with tumor size greater than 20 mm at diagnosis, and analysis of sequential serum specimens showed that ctDNA concentration in patients serum was related to tumor dynamics. We report that HPV mutational insertion constitutes a highly specific molecular marker of ctDNA in HPV-associated tumor patients. Using this original approach, ctDNA was detected in most cervical cancer patients over stage I and ctDNA concentration was found to reflect tumor burden. In addition to its potential prognostic and predictive value, HPV mutation insertion is likely to constitute a new molecular surrogate of minimal residual disease and of subclinical relapse in HPV-associated tumor. This is of major importance in the perspective of specific anti-HPV therapy.This publication has 19 references indexed in Scilit:
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Frequent genomic structural alterations at HPV insertion sites in cervical carcinomaThe Journal of Pathology, 2010
- Human Papillomavirus DNA in Plasma of Patients with HPV16 DNA-positive Uterine Cervical CancerJapanese Journal of Clinical Oncology, 2010
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literatureCritical Reviews in Oncology/Hematology, 2008
- The Majority of Viral-Cellular Fusion Transcripts in Cervical Carcinomas Cotranscribe Cellular Sequences of Known or Predicted GenesCancer Research, 2008
- Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNACancer Research, 2007
- Quantification of human papillomavirus DNA in the plasma of patients with cervical cancerInternational Journal of Gynecologic Cancer, 2004
- Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesionsOncogene, 2002
- Low Incidence of HPV DNA in Sera of Pretreatment Cervical Cancer PatientsGynecologic Oncology, 2001